Article
Increased acquired protease inhibitor drug resistance mutations in minor HIV-1 quasispecies from infected patients suspected of failing on national second-line therapy in South Africa.
BMC infectious diseases - 25 Feb 2021
Obasa Adetayo Emmanuel, Ambikan Anoop T, Gupta Soham, Neogi Ujjwal, Jacobs Graeme Brendon
Abstract excerpt
BACKGROUND: HIV-1C has been shown to have a greater risk of virological failure and reduced susceptibility towards boosted protease inhibitors (bPIs), a component of second-line combination antiretroviral therapy (cART) in South Africa. This study entailed an evaluation of HIV-1 drug resistance-associated mutations (RAMs) among minor viral populations through high-throughput sequencing genotypic resistance...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.